Prediction of Intervention Effects in Health Systems: Johns Hopkins HealthCare Diabetes Case Study by Scott, Emily
Prediction of Intervention Effects in
Health Systems: Johns Hopkins
HealthCare Diabetes Case Study
by
Emily Scott
A thesis submitted to The Johns Hopkins University




© 2019 Emily Scott
All rights reserved
Abstract
We use administrative, claims, and clinical data from Johns Hopkins Health-
Care (JHHC) to investigate (1) plan members’ health states and health state
trajectories, and (2) optimal interventions to improve population health at
more affordable costs. Our study population consists of 56,349 members,
27,636 (49%) of whom have an ICD-10 diabetes diagnosis.
We use a simulation-based approach to predict intervention effects and
their uncertainty. Our prediction of intervention effects (PIE) model is com-
posed of seven component models corresponding to member enrollment,
health state, probability of positive expenditure, size of positive expendi-
ture, and disenrollment due to death, changing plan, or other reasons. We
apply our PIE model to two interventions targeted to diabetic members:
(1) reducing the effect of diabetes on health state and expenditure by
0-5% and (2) reducing patients’ plasma glucose concentration (HbA1c) by
0-1%.
ii
We find that diabetic patients have worse health states, higher probability
of positive expenditure, and greater magnitude positive expenditure than
otherwise similar non-diabetic patients. Diabetic members have lower hazard
of disenrollment due to death, changing plan given survival, and disenrolling
for other reasons given survival and not changing plan than otherwise similar
non-diabetic patients.
In our first intervention, we predict $60 in monthly savings per diabetic
member if we reduce the effect of diabetes on both health state and expenditure
by 2.5%. In our second intervention, we predict $200 in monthly savings per
Medicare Advantage member if we reduce HbA1c by 0.7%.
We propose our PIE model as a decision-support tool to quantitatively
evaluate the relative merits of different interventions. One of its strengths is
its flexibility; the component models can be adapted to the scientific question
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Societies have practiced medicine for millennia. In its earliest forms, the
distinction between medicine, magic, and religion was poorly defined. Various
ailments, now understood to have biological explanations, were ascribed to
curses cast by the Gods. Treatments were crude and sometimes did more harm
than good. Ancient Greek physician Hippocrates was the first to propose that
medical conditions have natural, rather than supernatural, explanations. He
coined the maxim, "first, do no harm" (primum non nocere) and is credited by
many with developing the theory of the four humours. He proposed that the
four humours—blood, yellow bile, black bile, and phlegm—could explain all
bodily functions and dysfunctions. This theory advocated for such practices as
bloodletting when the physician believed a patient’s condition was due to an
overabundance of blood and thus a systemic imbalance. Despite Hippocrates’
fundamental belief in a physician’s obligation to do no harm, bloodletting
was generally more detrimental than beneficial to the patient.
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Throughout history, physicians have sought to tailor their medical care to
the individual; they have used their judgment to prescribe the treatment they
believe will yield the best therapeutic benefit. However, even physicians with
the best of intentions are not infallible. As history has shown, their judgments
can be inadequately supported by data and sometimes misguided. Medicine
has evolved beyond measure between Hippocrates’ life and now—life ex-
pectancy is increasing, cancer survival rates are improving, and diagnostic
tools are more sensitive, among other metrics of improvement. Individualized
medicine is entering its latest iteration: precision medicine. Precision medicine
uses all available data to provide the best supported behavioral and medical
interventions. Best medical practice should be continually refined as indicated
by new data so that patients can attain their best possible outcomes and live
their best possible lives.
1.2 National Healthcare Expenditure
The Organization for Economic Cooperation and Development (OECD) was
established in 1961 to encourage international collaboration and problem-
solving. There are 36 OECD countries, including the United States, that
cooperate to develop data-driven policy recommendations. The OECD coun-
tries are international leaders in economic, social, and health policy and will
be referenced to contextualize health expenditure and health outcomes in the
United States.
2
The United States spent $3.5 trillion on healthcare in 2017 (OECD, 2017).
National healthcare expenditure is predicted to grow by 5.5% per year through
2027 (CMS, 2017). Despite ever-increasing costs, health outcomes have not
improved to match. The US is falling behind other OECD countries in myriad
health measures while outpacing them in expenditure (Sawyer and McDer-
mott, 2019). More than concerning, the trend is unsustainable as national
healthcare expenditure is growing more rapidly than the economy. The US
spent 17.2% of GDP on healthcare in 2017 (Figure 1.1). It is predicted to reach
19.4% by 2026 (Cuckler et al., 2018).
Figure 1.1: Percent of GDP spent on healthcare in OECD countries from 2005 to 2017.
The US has consistently spent the largest percent of GDP on healthcare out of the
OECD countries. The OECD countries with the next highest percent GDP spent on
healthcare in 2017 are Switzerland, France, and Germany which spent 12.3, 11.5, and
11.3%, respectively (OECD, 2017).
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The unchecked growth of national healthcare expenditure and the burden
this places on patients and payers are not without hope. There is an estimated
34% waste in the healthcare expenditure (Berwick and Hackbarth, 2012),
where waste is understood to be "outlays for health services that could be elim-
inated without harming consumers or care quality" (O’Neill and Scheinker,
2018). That 34% translates to over $1 trillion. Recovering even some frac-
tion of this waste offers enormous opportunity to make quality healthcare
more affordable for patients, providers, and payers. Further, such savings
could be redirected to value-adding public policies that have historically been
preempted by national healthcare costs.
1.3 Diabetes: A Public Health Crisis
1.3.1 Epidemiology
Diabetes is a metabolic disease in which the body produces little to no insulin
or cannot effectively use insulin (NLM, 2019). Insulin is a hormone necessary
to transport glucose—a major source of energy—from the blood stream to
cells. When insulin is poorly regulated, patients are at risk for hyper- and
hypoglycemia;1 either imbalance can cause adverse systemic effects up to and
including death (Mayo Clinic, 2019). In the long-term, poorly regulated blood
sugar can lead to complications such as blindness and predispose diabetics to
other conditions such as cardiovascular disease and kidney disease.
1Hyper- and hypoglycemia refer to high and low blood sugar, respectively.
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The prevalence of diabetes has grown consistently since the 1950s. In
1958, less than 1% of the population had a diabetes diagnosis; by 2015 that
number had risen to 7.4% (CDC, 2017a). Between 1980 and 2012, both the
prevalence and incidence of diabetes doubled (Geiss et al., 2014). The latest
reports estimate that 30.3 million people in the US have diabetes (9.4% of the
population), 23.8% of whom do not know they have the disease (CDC, 2017b).
The percent of people with diabetes increases with age; 25.2% of people over
65 have diabetes (CDC, 2017b).
These patterns are highly concerning for both the patient and payer. For
the patient, the number of complications and coexisting conditions associ-
ated with diabetes can reduce both quality and length of life. In 2014, 7.2
million hospital discharges listed diabetes as one of the diagnoses; the pri-
mary reasons for these hospitalizations include major cardiovascular disease,
lower-extremity amputation, and diabetic ketoacidosis (CDC, 2017b). There
were an additional 14.2 million emergency room visits which listed diabetes
as one of the diagnoses; approximately one third of these visits were due to
hyper- or hypoglycemia (CDC, 2017b). For the payer, the concerns are obvious:
diabetes and its associated complications, comorbidities, and hospitalizations
compromise their member’s health and are expensive.
1.3.2 Cost
The estimated cost of diabetes in 2012 was $245 billion (CDC, 2017b). Diabetic
patients are estimated to have annual medical expenditure of $13,700, over
half of which can be attributed to diabetes (CDC, 2017b). Insulin-dependent
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diabetics cannot survive without insulin injections; however, the price of
insulin nearly tripled between 2009 and 2017 from $92.70 to $274.70 (Kaiser
Health News, 2019). Patients, especially those without medical insurance, are
forced to make difficult decisions about what sacrifices they can make to afford
their life-saving medication. Some are pushed to sell personal belongings
and tap retirement funds to pay for their prescriptions (Prasad, 2019) or, in
extreme cases, ration insulin which can lead to premature and preventable
death (Sable-Smith, 2018). The cost of diabetes extends beyond dollars; it costs
lives. Patients deserve evidence-based interventions to improve their health
at more affordable costs.
1.3.3 Interventions
Many risk factors for diabetes can be managed through behavioral interven-
tions. Smoking, obesity, physical inactivity, and high blood pressure are
all associated with increased risk of diabetes (CDC, 2017b). Interventions
that encourage smoking cessation, diet, and exercise can delay or prevent
development of diabetes as well as help manage symptoms in existing cases.
One such intervention is the National Diabetes Prevention Plan (National
DPP). The National DPP was first evaluated in a randomized clinical trial
lasting 2.8 years. 3,150 adults at high-risk for developing diabetes were ran-
domized to lifestyle intervention, metformin,2 or placebo. Those in the first
group realized the greatest benefit with a 58% reduction in diabetes incidence
2Metformin is an oral medication used to treat high blood sugar. It promotes production
of and sensitivity to insulin in the body. It is the most common treatment for non-insulin
dependent diabetics.
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as compared to placebo (Diabetes Prevention Program Research Group, 2009).
An extended follow-up lasted for seven additional years; at the end of the ex-
tended follow-up (i.e. 10 years since randomization), those patients who were
assigned to lifestyle intervention experienced a 34% reduction in cumulative
incidence of diabetes as compared to placebo (Diabetes Prevention Program
Research Group, 2009). The National DPP offers persisting benefits up to at




2.1 Healthcare Expenditure Data
Healthcare expenditure data are often positively skewed. This pattern is
driven by a few patients having very large medical expenditures relative to the
majority of patients with more moderate, usual-care expenses. Additionally,
healthcare expenditure data are often heteroscedastic. The variance tends
to increase with increasing mean (Blough and Ramsey, 2000). Two common
approaches to analyzing these data are log-linear models and two-part models
(Duan et al., 1983).
Healthcare expenditure data can be analyzed using a log-linear model if
the error terms after log-transformation are both Gaussian and homoscedastic.
Predicted values from this approach are in terms of log dollars and need to
be retransformed to obtain predicted values in dollars. This retransformation
is accomplished by exponentiating predicted log dollars and multiplying by




where σ̂2 denotes the estimated mean
squared error (Duan et al., 1983).
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Two-part models are used when the healthcare expenditure data have
a large proportion of zeros; this happens when many individuals have no
expenditure in at least one of the measurement intervals (Blough and Ramsey,
2000). Two-part models are based on mixed probability distributions and treat
expenditure as arising from two processes: (1) the probability of a positive ex-
penditure, and (2) the size of the expenditure conditioned on it being positive
(Blough and Ramsey, 2000). The probability of a positive expenditure can be
expressed as a probit model and the size of the expenditure conditioned on it
being positive can be expressed as a log-linear model (Duan et al., 1983). The
predicted expenditure is the product of the probability of positive expenditure,
the size of the expenditure given it is positive, and the retransformation factor.
Duan proposes the smearing coefficient 1n ∑
n
i=1 exp{ε̂i} as an alternative
to the retransformation factor in log-linear regression (Duan, 1983).1 The
smearing coefficient can outperform the retransformation factor because
exp{x0β̂ + σ̂2/2} is not always consistent for E[Y0], where x0 denotes the
design matrix, β̂ denotes the least squares regression coefficients, σ̂2 denotes
the mean squared error, and Y0 denotes the response.2 Duan demonstrates
that the smearing estimate 1n ∑
n
i=1 exp{x0β̂ + ε̂i} is consistent when the re-
transformation function is continuously differentiable. In the case of log-linear
regression, the retransformation function is the exponential which is continu-
ously differentiable; thus, the smearing estimate is consistent (Duan, 1983).
1The smearing coefficient can be used for other transformations but we will specifically
discuss it with respect to log-transformation.
2exp{x0 β̂ + σ̂2/2} is consistent for exp{x0β + σ2/2} whether or not the error terms follow
a Gaussian distribution. exp{x0 β̂ + σ̂2/2} may not be consistent for E[Y0] when the error
terms do not follow a Gaussian distribution.
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2.2 Causal Framework
Suppose we are interested in the causal effect of some exposure variable A
on an outcome variable Y. Let A be a binary exposure variable where A = 0
when there is no exposure and A = 1 when there is an exposure. Then define
Ya=0 to be the outcome under exposure a = 0 and Ya=1 to be the outcome
under exposure a = 1 (Hernán, 2004). Hernán writes that the exposure A
has a causal effect if Ya=0 ̸= Ya=1. This is the concept of an individual causal
effect (Hernán, 2004). However, this definition presents what Holland terms
the "Fundamental Problem of Causal Inference"; he writes that we cannot
observe both Ya=0 and Ya=1 on the same unit and it is therefore impossible
to observe the effect of A (Holland, 1986). There are various frameworks
designed to address the Fundamental Problem of Causal Inference, such as
the Rubin Causal Model. While the individual causal effect is inherently
unobservable, the average causal effect can be estimated from the observed
individual outcomes and is equal to T = E[Ya=1 − Ya=0] (Holland, 1986).
However, estimating the average causal effect necessarily requires multiple
units.
In this thesis, the unit of study is the Johns Hopkins HealthCare system
(i.e. N = 1); we are interested in estimating the system-wide causal effect of
various interventions. We cannot observe the system under both observed and
intervention conditions. We propose a simulation-based approach to predict
the causal effects of various interventions.
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2.3 Restricted Latent Class Models
An individual’s health state cannot be directly measured. However, observed
clinical data can help to understand latent health state. One approach to
modeling latent health state is to use Restricted Latent Class Models (RLCMs).
Xu and Shang describe a family of RLCMs: suppose we collect J binary
responses for a subject; these responses can be stored in a J × 1 vector R.
Assume that these responses can be explained by K binary latent attributes;
these attributes can be stored in a K × 1 vector α. Define a binary K × L
Q-matrix that reflects known relationships between R and α (Xu and Shang,
2018). Wu et al. (2019) "define clusters to be comprised of those observations
with identical latent states." Two individuals i and j would be in the same
cluster if αi = αj. Wu et al. (2019) propose scientifically structured clustering
as a Bayesian method to estimating these clusters when the Q-matrix and the
number of distinct clusters are unknown. This approach can be used to cluster
patients with shared latent health states. Prior knowledge from clinical data




A Brief Tour of the JHHC Data
We use monthly Johns Hopkins HealthCare (JHHC) data from July 2017
through June 2018. Our raw dataset includes every JHHC member with an
ICD-10 diabetes diagnosis during this period (n = 28, 489). It also includes
two non-diabetic members for each diabetic member (n = 56, 920). These
non-diabetics were randomly sampled from the remaining JHHC member
base (n = 467, 274). Our resulting dataset includes 85, 409 members. Of these,
we consider only persons who are 18 years of age or older and have nonzero
Resource Utilization Band (RUB) scores (see section 3.2). After filtering by
these criteria, there are 56, 349 patients in our study population, 27, 636 (49%)
of whom have an ICD-10 diabetes diagnosis.
These patients are enrolled in one of JHHC’s four lines of business: Em-
ployer Health Programs (EHP), Medicare Advantage (MA), Priority Partners
(PP), and US Family Health Plan (USFHP) (“About Us”). The total number of
members and member-months by line of business and diabetes diagnosis are
summarized in Table 3.1 and Table 3.2.
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Table 3.1: Non-diabetic and diabetic members by line of business
Line of Business Non-diabetic Members Diabetic Members Total
Members (%) Members (%) Members (%)
EHP 5, 462 (9.7) 3, 482 (6.2) 8, 944 (15.9)
MA 1, 123 (2.0) 3, 578 (6.3) 4, 701 (8.3)
PP 18, 197 (32.3) 15, 640 (27.8) 33, 837 (60.0)
USFHP 3, 931 (7.0) 4, 936 (8.7) 8, 867 (15.7)
Total 28, 713 (51.0) 27, 636 (49.0) 56, 349 (100)
Table 3.2: Non-diabetic and diabetic member months by line of business
Line of Business Non-diabetic Members Diabetic Members Total
Member months (%) Member Months (%) Member Months (%)
EHP 53, 521 (10.1) 33, 030 (6.2) 86, 551 (16.3)
MA 10, 000 (1.9) 29, 904 (5.6) 39, 904 (7.5)
PP 172, 666 (32.6) 139, 481 (26.3) 312, 147 (58.8)
USFHP 40, 278 (7.6) 51, 532 (9.7) 91, 810 (17.3)
Total 276, 465 (52.1) 253, 947 (47.9) 530, 412 (100)
MA has more than three diabetic patients to every one non-diabetic patient
despite our overall study population having an approximately equal number
of diabetic and non-diabetic patients. This feature makes it an interesting
target for diabetes intervention programs. EHP has the opposite pattern with
approximately one diabetic patient to every two non-diabetic patients. PP and
USFHP have more balanced numbers of non-diabetics and diabetics.
MA has the fewest months of observation per individual (i.e. member
months per member) and USFHP has the highest months of observation per
individual. Diabetics tend to have somewhat fewer months of observation
than their non-diabetic counterparts, except in USFHP. These patterns can be
seen in Figure 3.1.
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Figure 3.1: Months of observation by line of business and diabetes status. The median
number of months of observation is 12 for non-diabetic patients in all lines of business.
The median number of months of observation is 12, 10, 11, and 12 for diabetic patients
in EHP, MA, PP, and USFHP, respectively. USFHP has the highest member retention.
3.1 Population Demographics
We did not match on age, sex, or plan when obtaining our representative
sample of non-diabetics because we wanted it to be just that—representative.
There are imbalances in the JHHC population and we wanted to maintain
these so our predicted intervention effects are reflective of what might be
attained in the true population.
Non-diabetic members tend to be younger than diabetic members (Fig-
ure 3.2); on average, non-diabetic members are 39.8 years old (sd = 16.1) and
diabetic members are 55.3 years old (sd = 14.6) (Table 3.3). All subsequent
analyses adjust for age so estimated diabetes effects are not an artifact of
differing age distributions.
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Figure 3.2: Age distribution by line of business and diabetes status.
PP members tend to be the youngest (mean age = 41.5), followed by EHP
(mean age = 45.0), USFHP (mean age = 59.6), and MA (mean age = 70.8).
These age differences have ramifications for each line of business as older
members tend to have worse health states and higher expenditures (section 3.2,
section 3.3).
Table 3.3: Non-diabetic and diabetic member age by line of business
Line of Business Non-diabetic Members Diabetic Members Total
Mean (SD) Mean (SD) Mean (SD)
EHP 39.8 (13.7) 53.2 (11.7) 45.0 (14.5)
MA 70.7 (9.7) 70.8 (8.7) 70.8 (8.9)
PP 35.4 (13.2) 48.7 (11.8) 41.5 (14.2)
USFHP 51.0 (17.8) 66.4 (12.9) 59.6 (17.1)
Total 39.8 (16.1) 55.3 (14.6) 47.4 (17.3)
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3.2 Population Health
We have two measures of health state: (1) Resource Utilization Band (RUB)
score as a macro-level measure of health state, and (2) plasma glucose concen-
tration (HbA1c) as a micro-level measure of health state specific to estimating
how well-controlled a case of diabetes is, if present.
3.2.1 Health State
We use RUB score as a proxy for health state. RUB scores are not derived from
an individual’s health data; rather, they are a measure of the extent to which
an individual utilizes medical resources. An individual with a RUB score of
1 is a low utilizer and an individual with a RUB score of 5 is a high utilizer,
with 2, 3, and 4, as intermediate and ordered levels of utilization. RUB score
is an imperfect measure of health state. In subsection 6.2.2, we discuss future
plans for improving this aspect of our approach as more clinical data are made
available.
Diabetics obviously have poorer health states and higher RUB scores than
otherwise similar non-diabetics. This can be seen in Figure 3.3; the proportion
of non-diabetic members with RUB score 1 or 2 is greater than the proportion
of diabetic members with RUB score 1 or 2 in all age strata. The same is true
for RUB score 3 in all but the youngest age stratum (18-25 years of age). The
pattern reverses for RUB scores 4 and 5, with a greater proportion of diabetic
patients falling into these categories than non-diabetics in all age strata.
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Figure 3.3: Proportion of population falling into each RUB score category by diabetes
diagnosis and age. Age categories are displayed in the banner over each plot and
show age in years.
3.2.2 Plasma glucose concentration (HbA1c)
We use plasma glucose concentration (HbA1c) as a clinically-grounded mea-
sure of diabetes health state. We have 10, 964 member-months of HbA1c
data out of 530, 412 member-months (2%). HbA1c less than 5.7%, between
5.7-6.5%, and greater than 6.5% are diagnosed as non-diabetic, pre-diabetic,
and diabetic, respectively (American Diabetes Association, 2019). In our study
population, the median HbA1c measurements in non-diabetic, pre-diabetic,
and diabetic patients are 5.4%, 6.1%, and 7.0%, respectively (Figure 3.4).
17
Figure 3.4: Plasma glucose concentration by diabetes diagnosis.
3.3 Population Expenditure
We explore patterns in "per member per month (PMPM)" expenditure where
PMPM expenditure is defined to be average monthly expenditure per member.
Figure 3.5 shows the relationship between diabetes, age, and PMPM expen-
diture. We see that there are more non-diabetics than diabetics in the three
youngest age strata (18-25, 26-35, 36-45 years of age). Diabetics become more
prevalent than non-diabetics at age 46-55 and remain so in all subsequent
strata. We standardize the frequency plots to density plots to more clearly see
the relative distributions of PMPM expenditure (Figure 3.6). Diabetic patients
have higher PMPM expenditure than non-diabetic patients. The difference
between PMPM expenditure in non-diabetic and diabetic patients becomes
less pronounced with increasing age.
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Figure 3.5: Frequency of Per Member Per Month Expenditures by Age Category
Figure 3.6: Density of Per Member Per Month Expenditures by Age Category
19
There are more members with near-zero PMPM expenditure in the younger
age strata, especially in the non-diabetic population (Figure 3.6). These low
PMPM expenditures are driven by patients with a high proportion of months
with no expenditure. Across the population, 31.2% of monthly expenditure
records are zero. 36, 147 patients out of 56, 349 have at least one month in
which they have no medical expenditure. 19, 810 (55%) of these are between
18 and 45 years old.
If we further stratify diabetes status to include non-diabetic, pre-diabetic,
and diabetic populations, we see the pre-diabetic patients have a more diffuse
distribution that falls approximately between that of the non-diabetics and
diabetics (Figure 3.7).
Figure 3.7: Density of Per Member Per Month Expenditure by Diabetes Diagnosis
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3.4 Population Disenrollment
We group disenrollment into three categories: (1) disenrollment due to death,
(2) disenrollment due to changing plan, and (3) disenrollment for other reasons.
There are a total of 322 deaths (0.6% of population), 304 plan changes (0.5% of
population), and 9, 917 disenrollments for other reasons (18% of population).
Counts of deaths, plan changes, and disenrollments for other reasons are
stratified by RUB score and diabetes status in Table 3.4, Table 3.5, and Table 3.6.
Table 3.4: Non-diabetic and diabetic member deaths by RUB Score
RUB Score Non-diabetic Members Diabetic Members Total
N (%) N (%) N (%)
1 5 (1.6) 2 (0.6) 7 (2.2)
2 6 (1.9) 0 (0.0) 6 (1.9)
3 16 (5.0) 6 (1.9) 22 (6.9)
4 18 (5.6) 22 (6.8) 40 (12.4)
5 84 (26.1) 163 (50.6) 247 (76.7)
Total 129 (40.1) 193 (59.9) 322 (100)
Table 3.5: Non-diabetic and diabetic member plan changes by RUB Score
RUB Score Non-diabetic Members Diabetic Members Total
N (%) N (%) N (%)
1 53 (17.4) 0 (0.0) 53 (17.4)
2 34 (11.2) 0 (0.0) 34 (11.2)
3 132 (43.4) 2 (0.7) 134 (44.1)
4 51 (16.8) 3 (1.0) 54 (17.8)
5 23 (7.5) 6 (2.0) 29 (9.5)
Total 293 (96.4) 11 (3.6) 304 (100)
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Table 3.6: Non-diabetic and diabetic member disenrollments due to other reasons by
RUB Score
RUB Score Non-diabetic Members Diabetic Members Total
N (%) N (%) N (%)
1 1271 (12.8) 47 (0.5) 1318 (13.3)
2 1351 (13.6) 39 (0.4) 1390 (14.0)
3 3776 (38.1) 516 (5.2) 4292 (43.3)
4 1694 (17.1) 491 (5.0) 2185 (22.0)
5 388 (3.9) 344 (3.5) 732 (7.4)
Total 8480 (85.5) 1437 (14.5) 9917 (100)
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Chapter 4
Methods for Prediction of
Intervention Effects (PIE)
We use administrative, claims, and clinical data from JHHC to model member
enrollment, health state, medical expenditure, and disenrollment. We use
these models to develop a simulation-based approach to predicting interven-
tion effects and their uncertainties.
4.1 Observed System Hierarchical Models
4.1.1 Enrollment
We explore enrollment by looking for spatial patterns in the state of Maryland.
Spatial patterns of interest include (1) which regions have the most diabetic en-
rollees and (2) which regions have the highest proportion of diabetic enrollees.
We model the observed counts using Poisson regression and the observed
proportions using binomial regression as a smooth function of the centroids
of each ZIP code. We then visually assess the estimated distributions.
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4.1.2 Health State Given Enrollment
We use Resource Utilization Band (RUB) score as a proxy for health state.
As discussed in section 3.2, an individual with a RUB score of 1 is a low
utilizer and an individual with a RUB score of 5 is a high utilizer, with 2,
3, and 4, as intermediate and ordered levels of utilization. Note that RUB
score is categorical; however, we model RUB score as if following a Gaussian
distribution. Specifically, we model RUB score as a linear function of diabetes
status, sex, a smooth function of age, and a smooth function of month with
random intercepts and slopes at the individual level. We allow the effect of
diabetes to differ by sex and age.
4.1.3 Expenditure Given Enrollment and Health State
As discussed in section 3.3, 31.2% of monthly expenditure records are zero.
Due to the high proportion of zeros, we model the probability of having
a positive expenditure and the size of the positive expenditure as separate
processes. We model the log odds of having a positive expenditure as a linear
function of RUB score, diabetes status, sex, a smooth function of age, and a
smooth function of month with random intercepts at the individual level. Due
to the positive skew of medical expenditure data, we model log expenditure
as a linear function of RUB score, diabetes status, sex, a smooth function of
age, and a smooth function of month with random intercepts and slopes at
the individual level. We allow the effect of diabetes to differ by sex, age, and
RUB score. We allow the effect of age to differ by RUB score.
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We are ultimately interested in making predictions and inference on the
untransformed scale (i.e. dollars rather than log dollars), so we calculate the
smearing estimate 1n ∑
n
i=1 exp{x0β̂ + ε̂i} where x0 is the design matrix, β̂ are
the least squares estimates, and ε̂i are the least squares residuals (Duan, 1983).
The smearing estimate can be decomposed into the regression effect exp{x0β̂}
and the skewness effect or smearing coefficient 1n ∑
n
i=1 exp{ε̂i}. To allow
for heterogeneity in the relationship between the covariates and smearing
coefficient, we regress the exponeniated residuals on the same predictors as
were used in the original log-linear model. The predictions from this model
estimate the smearing coefficient for any combination of covariates.
4.1.4 Disenrollment Given Enrollment and Health State
We model disenrollment using a discrete-time hazard model, formulated
as three Poisson regression models: (1) disenrollment due to death in the
current month, (2) disenrollment due to changing plan given survival in the
current month, and (3) disenrollment for other reasons given survival and not
changing plan in the current month. We model disenrollment as a function
























































































































































































































































































































































We draw a random sample with replacement from the observed population.
Individuals are drawn with their respective covariates (i.e. age, sex, diabetes
status). Individuals are detached from the outcomes of interest (i.e. monthly
RUB score and expenditure). We expand the number of records associated
with each individual to include all months starting at the observed month
of enrollment up to month 12. For example, if an individual enrolled in the
observed population at month 3 and disenrolled at month 6, we enroll a
person with the same characteristic set of covariates at month 3 and retain
them in the population until either month 12 or the month in which any of the
disenrollment models predict their departure, whichever happens sooner.
4.2.2 Health state
We use the model-based distributions of fixed and random effects to simulate
health states in the following manner:
1. Obtain the fixed effects design matrix and call this X. This design matrix
contains columns corresponding to each of the covariates in the health
state model. X is a block matrix of N vertically stacked blocks, where N
is the number of individuals in the simulated population. The covariates
corresponding to individual i populate block i. The number of rows in each
block is determined by the month in which the corresponding individual
enrolled in JHHC; each block will have one row per month from the month
of enrollment through month 12.
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2. Obtain the random effects design matrix and call this Z. This design
matrix has a column of ones for the random intercepts and a column of
month numbers for the random slopes. As above, this will be a block
matrix composed of N vertically stacked blocks, where N is the number
of enrolled individuals in the simulated population. To illustrate, consider
two individuals i and j: if individual i enrolls in month 1, then block i of
the random effects design matrix will be a 12 × 2 matrix with a column
of ones and a column containing the values 1 through 12. If individual j
enrolls in month 3, block j of the random effects design matrix will be a
10 × 2 matrix with a column of ones and a column containing the values 3
through 12. The remaining blocks will be filled similarly.
3. Obtain a random sample from the model-based distribution of fixed effects
and call this βsim. The model-based distribution is multivariate Gaussian
with mean equal to the fixed effects coefficients β̂ and variance-covariance





4. For each individual i, obtain a random sample from the model-based
distribution of random effects and call this bsim,i; bsim,i will be a 2× 1 vector
with a random intercept and a random slope. The model-based distribution
is multivariate Gaussian with mean 0 and variance-covariance matrix equal






5. Obtain error terms εsim for each record. These will be drawn from a Gaus-






6. Calculate the simulated health states for each individual where [X]i refers
to block i of the fixed effects design matrix and [Z]i refers to block i of the
random effects design matrix:
RUBi = [X]iβsim + [Z]ibsim,i + εsim,i
7. Round the simulated RUB score to the nearest integer. If the nearest integer
is less than 1, set the RUB score equal to 1. If the nearest integer is greater
than 5, set the RUB score equal to 5.
4.2.3 Expenditure
4.2.3.1 Probability of Positive Expenditure
We expand the fixed effects design matrix from the health state simulation to
include a column for the simulation-based RUB score. We then use the model-
based distributions of fixed and random effects to simulate the probability of
positive expenditure in the same manner as that described in steps 3-6 above
(subsection 4.2.2).
Our simulated responses are log odds of positive expenditure in each
month. We transform these to be on the probability scale. To simulate whether
the expenditure is positive, we sample from a binomial distribution with
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probability of success equal to the simulated probability. For example, suppose
we obtain probability pij for individual i in month j. To simulate whether
individual i will have a positive expenditure in month j, we sample from a
binomial distribution with probability of success pij. If this yields a success,
then individual i has a positive expenditure in month j. If this yields a failure,
then individual i has no expenditure in month j.
4.2.3.2 Size of Positive Expenditure
We expand the fixed effects design matrix from the expenditure probability
simulation to include columns for the interaction between RUB score and
age, sex, and diabetes status. We then use the model-based distributions of
fixed and random effects to simulate the size of the medical expenditure in the
same manner as described in steps 3-6 above (subsection 4.2.2). Our simulated
responses are log dollars so we exponentiate to obtain dollars.
4.2.4 Disenrollment
We obtain the simulated probabilities of death, changing plan given survival,
and leaving for other reasons given survival and not changing plan in the
following abbreviated version of the procedure described in subsection 4.2.2:
1. Obtain the fixed effects design matrix X (n.b. the fixed effects design matrix
for our Poisson models is entirely contained within the fixed effects design
matrix for our log-linear model so can be easily obtained by selecting the
relevant columns).
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2. Obtain a random sample from the model-based distribution of fixed effects
for each Poisson model. The model-based distribution is multivariate
Gaussian with mean equal to the fixed effects coefficients β̂ and variance-
covariance matrix equal to the fixed effects covariance matrix V̂ .












3. Calculate the simulated probability for each event. Let pdeath,ij denote
the probability of death for individual i in month j, pchange,ij denote the
probability of changing plan given survival for individual i in month j, and
pother,ij denote the probability of leaving for other reasons given survival
and not changing plan for individual i in month j. Let [X]i denote block i
of the fixed effects design matrix.





pother,ij = exp {[X]iβsim, other}
4. Predict whether individual i will disenroll in month j by sampling from a
binomial distribution with probability of success equal to pdeath,ij, pchange,ij,
and pother,ij in turn. If any of the three trials yields a success, we predict
individual i disenrolls in month j.
5. Remove all records subsequent to an individual’s predicted disenrollment.
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4.3 Prediction of Intervention Effects
We propose the causal pathway shown in Figure 4.1. Each node corresponds
to one of the component models from section 4.1. This framework forms the
basis for our simulation-based approach to predicting intervention effects.
Figure 4.1: Eligible members enroll in JHHC and are assigned an initial health state.
Members have an initial expenditure which is influenced by this initial health state.
Longitudinal health state depends on previous health states and longitudinal expen-
diture depends on concurrent health state and previous expenditures. Members can
disenroll in any month as influenced by their health state and expenditure. Enroll-
ment, health state, expenditure, and disenrollment can each be influenced by diabetes
status and other demographic data such as sex and age.
To demonstrate, we simulate two interventions using our prediction of
intervention effects (PIE) model. The first intervention is to decrease the effect
of diabetes by 0-5% in the health state and expenditure models. The second is
to reduce patients’ plasma glucose concentration (HbA1c) by 0-1%.1 These
two interventions illustrate the flexibility of our approach because the health
state model takes a different form in each but the overarching structure of the
PIE model remains unchanged.
10-1% is an absolute (i.e. not percent) reduction in HbA1c. HbA1c is reported as a percent.
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4.3.1 Intervention 1: Reduce Diabetes Effect
We follow the same simulation procedure as defined above with small modifi-
cations to the health state and expenditure models. Specifically, we take the
simulated diabetes coefficient from each model and iteratively multiply it by


















In each iteration, we multiply the diabetes coefficient in the health state
model by α1 and the diabetes coefficient in the expenditure models by α2.
We sample (α1, α2) from a grid of the plane [0.95, 1]× [0.95, 1] such that we
obtain good coverage of the possible combinations of modifications to the
health state and expenditure models.2 All other coefficients remain the same
throughout the iterations.
The remainder of the simulation procedure proceeds exactly as above but
with β∗sim rather than βsim. We calculate (1) the improvement in mean RUB
score, (2) per member per month savings, and (3) annual savings for every
combination of (α1, α2).
2We have been using a 15 × 15 grid for a total of 225 combinations.
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4.3.2 Intervention 2: Reduce Average Plasma Glucose
We assume a causal relationship between HbA1c and medical expenditure
(Lissovoy, Ganoczy, and Ray, 2000). We subset the population to include only
those who are in Medicare Advantage and have HbA1c data, thereby obtaining
661 members and 999 member months. We replace the RUB score model with
a model for plasma glucose concentration. We follow the same simulation
procedure as above but in evaluating the counterfactual, we subtract 0-1 from
predicted HbA1c values (i.e. we modify one column of the design matrix). We






Between July 2017 and June 2018, there were 28,489 diabetic and 467,274
non-diabetic JHHC members. Thus, approximately 6.1% of JHHC members
were known diabetics during this time frame. This is somewhat lower than
the national average of 7.1% (CDC, 2017b).1 Our model of the proportion
of diabetics by Maryland ZIP code estimates higher proportions of diabetic
members in the southern end of the Eastern Shore, Washington County, and
east and west Baltimore (Figure 5.1).
The regions with the highest proportion of diabetics roughly correspond to
the regions with the largest absolute number of enrolled diabetics. Our model
of the number of diabetics by Maryland ZIP code estimates the highest number
of diabetic enrollees in the southern end of the Eastern Shore, and east and
west Baltimore. Washington County is estimated to have a high proportion of
diabetics but not a large absolute number of enrollees (Figure 5.2).
1The CDC estimates a national average of 9.4% but 23.8% of these cases are undiagnosed.
35
Figure 5.1: Smoothed percent of members who are diabetic by ZIP code
Figure 5.2: Smoothed number of diabetic members by ZIP code
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5.1.2 Health State
Recall that we use RUB score as a proxy for health state, with high RUB scores
indicating higher medical resource utilization than low RUB scores. Further,
recall that we model RUB score as continuous despite it being discrete. In our
model, we control for diabetes status, age, sex, and month.
Figure 5.3: Predicted RUB score for patients in January 2018 with 95% confidence
bands. The relationship between age and RUB score is the same in other months;
January 2018 was chosen for convenience.
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We estimate that a female diabetic patient will have a RUB score 0.82(0.044)
units higher than an otherwise similar non-diabetic patient. We estimate
that a male diabetic patient will have a RUB score 0.97(.045) units higher than
an otherwise similar non-diabetic patient. Though the estimated effect of
diabetes on health state is greater in male than female patients, non-diabetic
male patients have a RUB score 0.23(0.011) units lower than otherwise similar
non-diabetic female patients (Table 5.1). The result of males having a lower
baseline RUB score but higher estimated diabetes effect is that male and female
diabetics have very similar RUB scores to each other. Male diabetics still have
lower RUB scores than otherwise similar females but by less of a margin than
when comparing non-diabetic males and females. There is a strong positive
association between RUB score and age (i.e. worsening health state with
increasing age). Between 50-70 years of age, the separation between diabetics
and non-diabetics becomes less pronounced (Figure 5.3).






Female 2.315 0.017 140.25
Male 2.082 0.017 124.6
Diabetes
• Female 0.824 0.044 18.53
• Male 0.970 0.045 21.64
* β̂ corresponds to the mean effect for each subgroup.
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5.1.3 Expenditure
5.1.3.1 Probability of Positive Expenditure
We estimate that the odds of a diabetic patient having positive expenditure are
4.3 times that of an otherwise similar non-diabetic patient and that the odds
of a male patient having positive expenditure are 0.61 that of an otherwise
similar female patient (Table 5.2).






RUB 1 (ref) -1.174 0.035 -33.57
RUB 2 0.569 0.022 26.23
RUB 3 1.258 0.019 64.86
RUB 4 1.851 0.023 80.87
RUB 5 2.759 0.032 85.76
Diabetes 1.451 0.019 75.66
Male -0.486 0.017 -27.97
* β̂ for the reference group corresponds to the log odds of positive
expenditure. β̂ for all other groups corresponds to the log of the
odds ratio between that group and the reference group.
In Figure 5.4, we transform to the probability scale and explore the rela-
tionship between RUB score and positive expenditure stratified by diabetes
diagnosis. A diabetic patient with RUB score 1 has a similar probability of
positive expenditure to an otherwise similar non-diabetic with RUB score 3.
This suggests that the effect of diabetes on positive expenditure goes above
and beyond that explained by RUB score. Specifically, the probability of ex-
penditure for a diabetic patient is like that of otherwise similar non-diabetic
patient with a RUB score that is two units higher. We see this pattern for
diabetics with RUB scores 1, 2, and 3.
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Figure 5.4: Predicted probability of positive expenditure with 95% confidence bands.
5.1.3.2 Size of Positive Expenditure
We estimate that a diabetic patient’s monthly expenditure is approximately
2.3 times that of an otherwise similar non-diabetic patient’s. There is no
compelling evidence that the effect of diabetes differs between men and
women (Table 5.3).
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Estimated expenditure increases with increasing RUB score. A non-diabetic
patient with RUB score 2, 3, 4, or 5 spends 1.74, 2.57, 4.37, or 7.86 times that
of an otherwise similar patient with RUB score 1, respectively. The estimated
effect of increasing RUB score is somewhat lower in diabetic patients than
non-diabetic patients in all but RUB score 5. A diabetic patient with RUB score
2, 3, 4, or 5 spends 1.43, 2.33, 4.12, or 7.93 that of an otherwise similar patient
with RUB score 1, respectively.






RUB 1 (ref) 4.214 0.028 151.81
RUB 2 0.556 0.022 25.634
RUB 3 0.944 0.019 49.73
RUB 4 1.474 0.021 69.10
RUB 5 2.062 0.0282 73.80
Male 0.016 0.015 1.08
Diabetes 0.835 0.062 13.41
Diabetes : Male -0.031 0.020 -1.55
Diabetes : RUB 2 -0.198 0.039 -5.02
Diabetes : RUB 3 -0.096 0.033 -2.93
Diabetes : RUB 4 -0.058 0.035 -1.66
Diabetes : RUB 5 0.009 0.040 0.24
* β̂ for the reference group corresponds to the expected geometric
mean of log expenditure for non-diabetic female patients with
RUB score 1. β̂ for all other groups corresponds to the difference
in the expected geometric mean of log expenditure between that
group and the reference group.
To obtain meaningful predicted expenditures, we exponentiate predicted
log dollars and multiply by the smearing coefficient. Smearing coefficient
model results can be found in the the Appendix (chapter 7).
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Figure 5.5: Predicted size of positive expenditure after transforming from log dollars
to dollars and multiplying by the smearing coefficient.
In Figure 5.5 we see that diabetics with a positive expenditure have a
higher monthly average than otherwise similar non-diabetics with a positive
expenditure and that monthly expenditure tends to increase with increasing
RUB score. The predicted expenditures are largely unrelated to increasing
age after stratifying by diabetes diagnosis and RUB score. This pattern is
surprising and was further explored to confirm it is a feature of the observed
data (see chapter 7).
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5.1.4 Disenrollment
We explore disenrollment in three successive discrete-time hazards models
implemented using Poisson regression. The first explores the hazard of death.
We find that the hazard of death is approximately 50% lower in diabetics than
otherwise similar non-diabetics (Table 5.4). Given the same same age, gender,
diabetes status, and health state, the hazard of death is similar among patients
with RUB scores 1, 2, and 3. It is approximately 1.76 times higher for patients
with RUB score 4 than otherwise similar patients with RUB score 1, and 29.49
times higher for patients with RUB score 5 than otherwise similar patients
with RUB score 1 (Figure 5.6).
The second model explores the hazard of disenrollment due to changing
plan given survival. We find that the conditional hazard is approximately 97%
lower in diabetics than otherwise similar non-diabetics (Table 5.5). All else
equal, the conditional hazard of disenrollment due to changing plan is similar
across RUB scores, similar between male and female patients, and increases
with increasing age in non-diabetic patients (Figure 5.7).
The third model explores the hazard of disenrollment due to other reasons
given survival and not changing plan. We find that the conditional hazard is
approximately 75% lower in diabetics than otherwise similar non-diabetics
(Table 5.6). The conditional hazard is lowest in RUB scores 1, 2, and 3, and
decreases with increasing age (Figure 5.8).
A common theme in all three models is that diabetic patients have lower
hazard of disenrollment than non-diabetic patients. The effect of this phe-
nomenon is a long-term increase in the fraction of diabetics relative to their
respective rate of enrollment.
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Figure 5.6: Each panel shows the hazard of disenrollment due to death for a male
patient in January 2018. The five panels correspond to the five RUB scores, as indicated
by the banner over each plot.






RUB 1 (ref) -9.243 0.520 -17.79
RUB 2 -0.198 0.556 -0.356
RUB 3 -0.387 0.437 -0.885
RUB 4 1.017 0.417 2.44
RUB 5 3.384 0.398 8.50
Diabetes -0.683 0.122 -5.59
Male 0.379 0.113 3.35
* β̂ for the reference group corresponds to the log hazard
of disenrollment due to death. β̂ for all other groups corre-
sponds to the difference in log hazard between that group
and the reference group.
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Figure 5.7: Each panel shows the hazard of disenrollment due to changing plan given
survival for a male patient in January 2018. The five panels correspond to the five
RUB scores, as indicated by the banner over each plot.






RUB 1 (ref) -6.849 0.278 -24.64
RUB 2 -0.488 0.220 -2.22
RUB 3 -0.376 0.165 -2.29
RUB 4 -0.311 0.197 -1.58
RUB 5 0.145 0.243 0.60
Diabetes -3.404 0.315 -10.82
Male -0.197 0.124 -1.59
* β̂ for the reference group corresponds to the log hazard
of disenrollment due to changing plan given survival. β̂
for all other groups corresponds to the difference in log
hazard between that group and the reference group.
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Figure 5.8: Each panel shows the hazard of disenrollment for other reasons given
survival and not changing plan for a male patient in January 2018. The five panels
correspond to the five RUB scores, as indicated by the banner over each plot.






RUB 1 (ref) -3.456 0.500 -69.21
RUB 2 -0.024 0.038 -0.62
RUB 3 -0.059 0.032 -1.85
RUB 4 0.233 0.036 6.47
RUB 5 0.282 0.049 5.80
Diabetes -1.366 0.031 -43.57
Male -0.108 0.022 -4.96
* β̂ for the reference group corresponds to the log hazard
of disenrolling for other reasons given survival and not
changing plan. β̂ for all other groups corresponds to the





Our health state simulation does not resemble the observed health state dis-
tribution as closely as we would like it to. However, the simulated health
state distributions mimic many important features of the initial population.
Specifically, we see there tend to be fewer diabetics with RUB score 1 or 2 than
non-diabetics across all age strata. Both diabetics and non-diabetics have high
proportions of patients with RUB score 3 across age strata. The proportion
of diabetic patients with RUB score 4 or 5 surpasses that of the non-diabetics.
These are all patterns we noted in the observed population (section 3.2).
Figure 5.9: Each panel corresponds to one of eight age strata, as indicated by the age
interval in each banner. Each panel shows the simulated health state distribution
from 10 simulations. The bold line shows the observed health state distribution.
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5.2.2 Expenditure
Recall that our simulated PMPM expenditure is the product of three models:
probability of positive expenditure, size of positive expenditure, and smearing
coefficient. Our simulated PMPM expenditure distributions closely resemble
the observed expenditure distribution (Figure 5.10). One of the lines in each
panel corresponds to the observed PMPM expenditure distribution; the simu-
lated PMPM expenditure distributions mimic reality closely enough that the
observed distribution is indistinguishable from the simulated distributions.
PMPM expenditure is higher in diabetic patients than non-diabetic patients
and the margin separating the distributions diminishes with increasing age.
Our simulations appear to capture these important features of the observed
PMPM expenditure distribution.
Figure 5.10: Each panel corresponds to one of eight age strata, as indicated by the
age interval in each banner. Each panel shows the simulated PMPM expenditure




Our models for disenrollment due to death and changing plan perform well
in the simulations. Our model for disenrollment due to other reasons overesti-
mates the number of disenrollments by approximately 10%. In the observed
population, there are 322 deaths (0.6% of the population), 304 plan changes
(0.5% of the population), and 9,917 disenrollments for other reasons (18% of
the population). In 100 simulations, we predict an average of 311.8 deaths,
332.6 plan changes, and 1,1067.5 disenrollments due to other reasons. The
boxplots in Figure 5.11 show the spread of these predicted disenrollments.
The observed deaths, plan changes, and disenrollments due to other reasons
are also shown in Figure 5.11 for reference.
Figure 5.11: Simulated disenrollments by reason for disenrollment. Note that the
y-axes are not the same in each panel.
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5.3 Prediction of intervention effects
5.3.1 Intervention 1: Reduce Diabetes Effect
In our first intervention we reduce the effect of diabetes by 0-5% in both the
health state and expenditure models. We obtain a surface of intervention
effects for three outcomes of interest: (1) improvement in mean RUB score, (2)
per member per month savings, and (3) annual savings.
5.3.1.1 Health State
If the effect of diabetes on health state and expenditure were reduced by 2.5%,
we predict a mean improvement in RUB score of 0.02. There is no relationship
between the mean improvement in RUB score and the percent change in
diabetes effect on expenditure because the health state model precedes the
expenditure model. The mean predicted improvement as well as the 2.5, 25,
75, and 97.5% quantiles of improvement are shown in Figure 5.12
5.3.1.2 Expenditure
We calculate both the PMPM savings and annual savings under intervention
conditions (Figure 5.13, Figure 5.14). We see that directly reducing the effect
of diabetes on expenditure reduces cost more rapidly than reducing the effect
of diabetes on health state. For a 2.5% reduction in the effect of diabetes
on both health state and expenditure, we predict a mean PMPM savings of
$60 ($40-80). Across the entire population, this would amount to $15 million
savings ($10-20 million).
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Figure 5.12: Predicted improvement in RUB score. The top panel shows the mean
predicted improvement in RUB score. In the second row, the left and right panels
show the 25 and 75% predicted improvement in RUB score, respectively. The lower
left and right panels show the 2.5 and 97.5% predicted improvement, respectively.
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Figure 5.13: Predicted PMPM savings based on 10 simulations. The top panel shows
the mean predicted savings. In the second row, the left and right panels show the 25
and 75% predicted savings, respectively. The lower left and right panels show the 2.5
and 97.5% predicted savings, respectively.
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Figure 5.14: Predicted annual savings based on 10 simulations. The top panel shows
the mean predicted savings. In the second row, the left and right panels show the 25
and 75% predicted savings, respectively. The lower left and right panels show the 2.5
and 97.5% predicted savings, respectively.
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5.3.2 Intervention 2: Reduce Average Plasma Glucose
5.3.2.1 Expenditure
Recall our assumption of a causal relationship between HbA1c and medical
expenditure (Lissovoy, Ganoczy, and Ray, 2000). In our second intervention
we reduce the average plasma glucose concentration (HbA1c) by 0-1%2 in
all Medicare Advantage patients. We see a strong approximately linear rela-
tionship between the absolute reduction in HbA1c and the PMPM savings
(Figure 5.15). If HbA1c is reduced by 0.7%, as in the DECIDE program,3 we
predict a PMPM savings of $200.
Figure 5.15: Predicted per member per month savings based on 10 simulations. The
x-axis corresponds to absolute reduction in HbA1c (i.e. not percent reduction). The
estimate shown here was obtained by regressing the predicted savings in our PIE
model on a smooth function of the reduction in HbA1c. The shaded region is a 95%
confidence band.
20-1% is an absolute (i.e. not percent) reduction in HbA1c. HbA1c is reported as a percent.
3DECIDE is a program run by Hopkins that provides online or in-person training to





We propose a simulation-based approach to predicting intervention effects in
healthcare systems, henceforth termed the Prediction of Intervention Effects
(PIE) model. The approach can simulate the complex interplay between
health, utilization, expenditure, and time. One strength of this approach is
its flexibility; the basic framework can be expanded to incorporate additional
component models as dictated by the problem of interest. Additionally, the
component models can be manipulated separately or in conjunction with one
another to estimate a variety of interventions. We use two interventions to
illustrate the potential value of our PIE model.
6.1 Intervention case studies
6.1.1 Intervention 1: Reduce Diabetes Effect
In our first simulation, we reduce the effect of diabetes on health state and
expenditure by 0-5%. We calculate (1) improvement in mean RUB score, (2)
PMPM savings, and (3) annual savings.
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Since health state does not depend on expenditure in our model, the mean
improvement in RUB score is only a function of the reduction in the effect
of diabetes on health state. If we reduce the effect of diabetes by 2.5%, we
simulate a mean improvement in RUB score of 0.02 (0.1-0.3). This result makes
intuitive sense because our health state model estimates that a diabetic patient
will have a RUB score 0.82 units higher than an otherwise similar nondiabetic
in women and 0.97 units higher than an otherwise similar nondiabetic in
men. If we reduce each of these by 2.5% and take the average, we see an
improvement in RUB score of 0.2. This is reflected in the simulated system.
For a modest reduction in the effect of diabetes on health state and expen-
diture (2.5% in both models), we predict a mean PMPM savings of $60 ($40-80)
for diabetics. The PMPM savings is a valuable metric because certain subpop-
ulations might more easily attain these margins of improvement. For example,
a 2.5% reduction in the effect of diabetes on health state and expenditure in
the subset of poorly-controlled diabetics might be more feasible than in the
subset of diabetics who are already taking the necessary steps to minimize the
burden of their disease. A pilot intervention that targets 2,500 diabetics with
the goal of reducing the effect of their disease on health state and expenditure
could save JHHC $150,000 annually.
If the effect of diabetes could be reduced by 2.5% in the entire population,
we predict a mean annual savings of $15 million ($10-20 million). To realize
these savings would require large-scale and thus potentially expensive in-
terventions. Since the PIE model does not adjust for the cost of intervention
deployment, the $15 million in savings would have to be interpreted in the
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context of intervention cost. While not adjusted for intervention cost, the
annual savings metric provides a sense of the potential impact an intervention
could have when deployed plan-wide.
6.1.2 Intervention 2: Reduce Average Plasma Glucose
In our second simulation, we consider only Medicare Advantage patients.
This subpopulation has the highest proportion of diabetic patients and the
oldest age distribution out of the four lines of business. This combination
makes MA patients some of the most expensive in the JHHC plan; conse-
quently, interventions that could reduce their expenditure while improving
their health are in high demand. One such intervention aims to reduce plasma
glucose concentration (HbA1c) by 0.7%. We simulate reductions in HbA1c
ranging from 0-1%.1 We calculate PMPM savings and find that a 0.7% de-
crease in HbA1c would save approximately $200 per member per month. If
500 Medicare Advantage patients achieve this level of improvement, it could
save $1.2 million over the course of a year. If the 3,578 diabetic members in
Medicare Advantage achieve this level of improvement, it could save $8.6
million.
Since the MA patients tend to be older and sicker than the rest of the JHHC
population, we do not think this result can be generalized to other lines of
business; we suspect the PMPM savings in other lines of business would be
lower.
10-1% is an absolute (i.e. not percent) reduction in HbA1c. HbA1c is reported as a percent.
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6.2 Future model improvements
6.2.1 Enrollment
Our enrollment models currently smooth outcomes of interest over the state
of Maryland. However, beyond identifying interesting spatial patterns, these
results are not incorporated into the analysis. This aspect of our current
approach restricts the types of interventions that can be simulated. There is
value to refining these models such that questions pertaining to who enrolls
in the plan can be investigated. We hope to provide the flexibility to allow
geographic studies of who enrolls by ZIP code to inform evaluation of JHHC
marketing strategies. This modeling approach can also be used to assure and
document JHHC’s compliance with regulations about access to their plans.
In addition to modeling enrollment into JHHC, we can model enrollment
into particular interventions. By incorporating spatial data into our analyses,
we can identify regions rich in poorly-controlled diabetics or those with de-
teriorating health states; relevant interventions could be more aggressively
targeted to these regions. Understanding the spatial distribution of disease
could be especially valuable in cases where part of a proposed intervention is
administered in-person. A pilot intervention could be deployed specifically in
the region identified as having the greatest potential for improvement.
6.2.2 Health State
Health state is unobservable but can be approximated using clinical and claims
data. For example, we might be confident that an individual is a diabetic if they
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have (1) multiple plasma glucose readings that place them above the threshold
for diabetes, and (2) regular prescription claims for insulin. However, there
are less clear-cut cases, especially when the patient interacts infrequently
with the healthcare system. Infrequent utilization of health services could
be indicative of a healthy patient or a patient with poorly monitored and
managed conditions.
The problem of assigning each patient a time-varying health state becomes
even more complicated when we consider possible combinations of comor-
bidities as well as variable behavior with respect to disease control (e.g. two
patients might have diabetes and COPD diagnoses but behave very differently
with respect to managing these conditions; these patients, though sharing the
same diseases, do not share a health state). We have been using RUB score
as a crude estimate of health state. It has always been a placeholder for a
better health state variable. We plan to move our PIE model into PMAP so we
can take full advantage of the rich clinical data in this platform. We plan to
improve our health state model by using restricted latent class models (Wu
et al., 2019).
6.2.3 Expenditure
We currently have expenditure data aggregated to the monthly level (i.e.
PMPM expenditure). We hope to decompose the monthly expenditure data
into utilization and expenditure data. We believe that the pattern of utilization
is as important as the absolute number of dollars spent. Two patients with
the same PMPM expenditure could have very different underlying health
states that are not adequately captured by an amount spent in a given month.
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For example, one could have a large expenditure from a one-time emergency
room visit and the other could have a series of medium-cost expenditures due
to a chronic condition. The health state and expenditure trajectories of these
two patients should be very different even though their PMPM expenditure
might be the same.
6.3 Future directions
6.3.1 Individual prediction
With the aforementioned improvements to the health state measure we will
develop and implement a method to predict patient trajectories. If fully
incorporated into the PMAP system, the method can capitalize on the clinical
data therein. We envision the health state trajectory being dynamic in that it
will update as new data are entered into PMAP. This predicted trajectory could
function as a tool to identify patients who require intervention; if identified
early, patients can realize their maximum benefit and avoid deteriorating into
a health crisis.
6.3.2 Population prediction
We plan to develop a user-friendly interface such that these models can sup-
port evidence-based decision making. We want the PIE model to be flexible
enough that a wide variety of interventions could be evaluated for their ability
to improve population health at affordable costs. In the short-term, we plan
to develop a Shiny App that allows the user to adjust the model inputs (e.g.
HbA1c data vs. RUB score) and specify the change they want to make to one
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or more of the variables in one or more of the component models (e.g. reduce
HbA1c by 0.5% and reduce the effect of diabetes on expenditure by 2%).
6.4 Conclusion
Medicine has advanced beyond measure in the past few centuries, with such
milestones as the discovery of antibiotics and the advent of vaccines. Many
diseases and conditions that were formerly thought to be death sentences are
now preventable or treatable. However, as remarkable as the current state of
medicine is, there is still work to be done. Healthcare expenditure in the US
has grown unsustainably while measures of health quality have stagnated.
Many of the life-changing health innovations are inaccessible to the patients
who need them most due to health inequality and prohibitive costs. There
is an urgent need to reduce waste in national healthcare expenditure. One
approach to identifying cost-effective solutions is precision medicine.
Precision medicine is evidence-based, patient-focused, and necessarily
dynamic. It is built around the fundamental idea of allowing health data to
speak for themselves and inform the most appropriate monitoring, treatment,
and intervention plans for subpopulations of individuals with shared char-
acteristics. Precision medicine can act at various levels of granularity, from
genetic and genomic data to population data. Whether the proximal goal is a
treatment and monitoring regimen, or evaluation of the most cost-effective
and beneficial interventions, the ultimate goal of precision medicine is to
present patients with the best supported and most beneficial plan for them.
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We have both the data and the demand for the development of more
efficient and better targeted healthcare strategies. Shown here, we predict
intervention effects at the population level. We propose our PIE model as a
decision-support tool to quantitatively evaluate the relative merits of different
interventions. It is a flexible framework that can accommodate varied scenar-
ios. We will continue to refine the model through collaboration with others




7.1 Smearing coefficient results
Since we model expenditure on the log scale, we have to multiply by the
smearing coefficient when we retransform our predicted values from log dol-
lars to dollars. This is to adjust for the skewness in the observed expenditure
data. There is some heterogeneity in the predicted smearing coefficient by
RUB, diabetes status, and age. The smearing coefficient increases with increas-
ing RUB score in both diabetic and non-diabetic patients, though the spread
is much more pronounced in non-diabetic patients. We see it decrease with
age in the non-diabetic patients and remain relatively stable in the diabetic
patients (Figure 7.1).
7.2 Expenditure model results
We find that predicted expenditure is largely unrelated to increasing age after
stratifying by diabetes diagnosis and RUB. We return to the original data to
confirm that our models reflect observed patterns in the JHHC population.
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Figure 7.1: Smearing coefficient by RUB score, age, and diabetes diagnosis.
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Recall that there is a strong positive association between age and RUB
score (Figure 3.3, Figure 5.3); patients in higher age strata tend to have higher
RUB scores. We also see a strong positive association between RUB score and
PMPM expenditure (Figure 7.2). Thus, old patients tend to have high RUB
scores and consequent high expenditure. To confirm that there is minimal
effect of being old above and beyond that explained by health state, we look
at observed PMPM expenditure stratified by diabetes status, age, and RUB
score (Figure 7.3). In keeping with our model results, PMPM expenditure is
largely stable across the age strata.
Figure 7.2: Observed PMPM expenditure by RUB score.
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Figure 7.3: PMPM expenditure by RUB score and Age. The RUB scores are shown in
the banners on the right of each plot. The top row corresponds to RUB score 1 and
the bottom row corresponds to RUB score 5.
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